Risk factors influencing antibody responses to kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages 83-90

  Guadalupe, Moraima ^a   Pollock, Brad H ^a   Westbrook, Steven ^a,d   Redding, Spencer ^a,d   Bullock, Delia ^a   Anstead, Gregory ^d   Agan, Brian K ^b,c   Marconi, Vincent C ^b,c   Barbieri, Sharon ^a   Sankar, Vidya ^a   Rebeles, Jennifer ^a   Flahive, Yvette ^a   Schoolfield, John ^a   Wang, Linding ^a   Lei, Xiufen ^a   Dow, Dorothy ^a   Yeh, Chih Ko ^a,d   Dang, Howard ^a   Infante, Anthony J ^a   Gao, Shou Jiang ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DETERIORATION; FEMALE; HISPANIC; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS DETECTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; FEMALE; HERPESVIRUS 8, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SARCOMA, KAPOSI; VIRAL LOAD; VIRUS LATENCY;

EID: 78650687668     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181fdc928     Document Type: Article

References (41)

1. Greene W, Kuhne K, Ye FC, et al. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res. 2007;133:69-127.
2. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med. 1996;335:233-241.
3. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996;2:925-928.
4. Kedes DH, Operskalski E, Busch M, et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;2:918-924.
5. Miller G, Rigsby MO, Heston L, et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med. 1996;334:1292-1297.
6. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348: 1133-1138.
7. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995;346: 799-802.
8. Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS. 1996;10:175-180.
9. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335: 123-128.
10. Cattelan AM, Calabro ML, Aversa SM, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer. 1999;35: 1809-1815.
11. Cattelan AM, Calabro ML, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr. 2001;28:44-49.
12. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS. 2003;17:1847-1851.
13. Newton R, Carpenter L, Casabonne D, et al. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Br J Cancer. 2006;94:1504-1509.
14. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi's sarcoma-associated herpesvirus immune responses and viraemia. AIDS. 2004;18:485-493.
15. Campbell TB, Fitzpatrick L, MaWhinney S, et al. Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection. J Acquir Immune Defic Syndr. 1999;22: 333-340.
16. Cannon MJ, Dollard SC, Black JB, et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS. 2003;17:215-222.
17. Cattelan AM, Calabro ML, De Rossi A, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779-785.
18. Jones JL, Hanson DL, Chu SY, et al. AIDS-associated Kaposi's sarcoma. Science. 1995;267:1078-1079.
19. Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS. 1996;10:l101-1105.
20. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340:1063-1070.
21. Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/ Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr. 1999;21(Suppl 1):S11-S17.
22. Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:270-274.
23. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45-F49.
24. Pellet C, Chevret S, Blum L, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol. 2001; 117:858-863.
25. Pellet C, Chevret S, Frances C, et al. Prognostic value of quantitative Kaposi's sarcoma-associated herpesvirus load in posttransplantation Kaposi's sarcoma. J Infect Dis. 2002;186:110-113.
26. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357: 1352-1353.
27. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876-2882.
28. Power DG, Mulholland PJ, O'Byrne KJ. AIDS-related Kaposi's sarcoma in a patient with a normal CD4 count. Clin Oncol (R Coll Radiol). 2008; 20:97.
29. Laney AS, Peters JS, Manzi SM, et al. Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J Clin Microbiol. 2006;44:3734-3741.
30. Rabkin CS, Schulz TF, Whitby D, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis. 1998;178:304-309.
31. Spira TJ, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol. 2000;38:2174-2180.
32. Biggar RJ, Engels EA, Whitby D, et al. Antibody reactivity to latent and lytic antigens to human herpesvirus-8 in longitudinally followed homosexual men. J Infect Dis. 2003;187:12-18.
33. Zhou FC, Zhang YJ, Deng JH, et al. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol. 2002;76: 6185-6196.
34. Baillargeon J, Deng JH, Hettler E, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus infection among blood donors from Texas. Ann Epidemiol. 2001;11:512-518.
35. Fu B, Sun F, Li B, et al. Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China. J Med Virol. 2009;81: 1422-1431.
36. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506.
37. de Souza VA, Pierrotti LC, Sumita LM, et al. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count. J Med Virol. 2007;79:1562-1568.
38. Corchero JL, Mar EC, Spira TJ, et al. Comparison of serologic assays for detection of antibodies against human herpesvirus 8. Clin Diagn Lab Immunol. 2001;8:913-921.
39. O'Brien TR, Kedes D, Ganem D, et al. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi's sarcoma. J Infect Dis. 1999;180:1010-1017.
40. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20: 1645-1654.
41. Zhang YJ, Davis TL, Wang XP, et al. Distinct distribution of rare US genotypes of Kaposi's sarcoma-associated herpesvirus (KSHV) in South Texas: implications for KSHV epidemiology. J Infect Dis. 2001;183: 125-129.